Difficult conditions in the UK and postponed operations expected to affect Q2 for Coloplast

It will be hard to compare the figures in Coloplast's Q2 report with other periods, says Sydbank analyst Søren Løntoft Hansen, who expects the medtech company to be affected by difficult conditions in the UK and delayed operations.


An uphill battle in the UK, postponed operations due to covid-19 and a difficult basis for comparison with other quarters will be some of the most important themes in Coloplast's Q2 fiscal report, according to Danish financial institution Sydbank's Chief Equity Analyst Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs